Mankind Pharma has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. Often regarded as a Textbook brand in its category with a strong clinical legacy, Rivotril further strengthens Mankind Pharma`s presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio. The acquisition builds on Mankind Pharma`s growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company`s overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders. Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions. Powered by Capital Market - Live News

Mankind Pharma has allotted 23,256 equity shares under ESOP on 16 March 2026. Post allotment, the paid up equity share capital has increased to 41,28,28,328 equity shares having face value of Re 1/- each. Powered by Capital Market - Live News

Net profit of Mankind Pharma rose 7.50% to Rs 408.75 crore in the quarter ended December 2025 as against Rs 380.23 crore during the previous quarter ended December 2024. Sales rose 11.52% to Rs 3567.20 crore in the quarter ended December 2025 as against Rs 3198.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3567.203198.79 12 OPM %25.7725.51 - PBDT838.19675.50 24 PBT615.59488.33 26 NP408.75380.23 8 Powered by Capital Market - Live News

Mankind Pharma announced that ICRA has assigned the rating ICRA AA+; Stable / ICRA A1+ for debt facilities of the company including non-convertible debentures. The rating on commercial paper of ICRA A1+ has been withdrawn. Powered by Capital Market - Live News

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live News